$MCLE
Medicale Corp.

2022 Q3 Form 10-Q Financial Statement

#000168316822005330 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.35K $6.730K $6.640K
YoY Change 119.08% -2.75% -7.52%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $600.00 $600.00 $600.00
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $14.35K $6.730K $6.640K
YoY Change 119.08% -2.75% -7.52%
Operating Profit -$6.734K -$6.035K
YoY Change -2.63%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$14.35K -$6.730K -$6.640K
YoY Change 119.08% -2.75% -7.52%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.35K -$6.734K -$6.635K
YoY Change 119.08% -2.63% -7.53%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 $0.00 -$1.122K
COMMON SHARES
Basic Shares Outstanding 5.920M shares 5.920M shares 5.920M shares
Diluted Shares Outstanding 5.920M shares 5.920M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Cash & Equivalents $0.00 $0.00 $344.00
Short-Term Investments
Other Short-Term Assets $340.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $0.00 $0.00 $540.00
YoY Change -100.0% -100.0% -97.76%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $0.00 $7.800K
YoY Change -100.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $7.800K $8.400K
YoY Change -100.0% -23.53% -22.22%
TOTAL ASSETS
Total Short-Term Assets $0.00 $0.00 $540.00
Total Long-Term Assets $0.00 $7.800K $8.400K
Total Assets $0.00 $7.800K $8.940K
YoY Change -100.0% -74.98% -74.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $37.00K $34.00K $31.00K
YoY Change 48.0% 183.33% 158.33%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $54.77K $48.22K $42.63K
YoY Change 49.53% 46.21% 43.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $54.77K $48.22K $42.63K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $54.77K $48.22K $42.63K
YoY Change 49.52% 46.21% 43.1%
SHAREHOLDERS EQUITY
Retained Earnings -$80.49K -$66.14K
YoY Change 136.23%
Common Stock $592.00 $592.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$54.77K -$40.42K -$33.69K
YoY Change
Total Liabilities & Shareholders Equity $0.00 $7.800K $8.940K
YoY Change -100.0% -74.98% -74.38%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$14.35K -$6.734K -$6.635K
YoY Change 119.08% -2.63% -7.53%
Depreciation, Depletion And Amortization $600.00 $600.00 $600.00
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$3.550K -$2.940K -$3.030K
YoY Change 20.75% -11.45% -15.36%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.550K 2.590K 0.000
YoY Change 446.15% 1263.16% -100.0%
NET CHANGE
Cash From Operating Activities -3.550K -2.940K -3.030K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 3.550K 2.590K 0.000
Net Change In Cash -0.000000000001819 -350.0 -3.030K
YoY Change -100.0% -88.82% -112.68%
FREE CASH FLOW
Cash From Operating Activities -$3.550K -$2.940K -$3.030K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001827855
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-250025
dei Entity Registrant Name
EntityRegistrantName
Medicale Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1556944
dei Entity Address Address Line1
EntityAddressAddressLine1
Otar Lortkifanidze 16
dei Entity Address City Or Town
EntityAddressCityOrTown
Tbilisi
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
0114
dei City Area Code
CityAreaCode
702
dei Local Phone Number
LocalPhoneNumber
6054432
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
18475 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Address Country
EntityAddressCountry
GE
CY2022Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 usd
CY2021Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
200 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5920000 shares
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
0 usd
CY2021Q3 us-gaap Assets Current
AssetsCurrent
18675 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7800 usd
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9600 usd
CY2022Q2 us-gaap Assets
Assets
7800 usd
CY2021Q3 us-gaap Assets
Assets
28275 usd
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
34000 usd
CY2021Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
25000 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
14220 usd
CY2021Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
11630 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
48220 usd
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
36630 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
592 usd
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
592 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25128 usd
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25128 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66140 usd
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34075 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-40420 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-8355 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7800 usd
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28275 usd
CY2022Q2 us-gaap Revenues
Revenues
0 usd
CY2021Q2 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6734 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6916 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32065 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25605 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6734 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6916 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-32065 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-25605 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6734 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6916 usd
us-gaap Net Income Loss
NetIncomeLoss
-32065 usd
us-gaap Net Income Loss
NetIncomeLoss
-25605 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5920000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4524449 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5920000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4524449 shares
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-1403 usd
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-11514 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-12917 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25200 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7175 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
5108 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6916 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-1808 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-8355 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-18696 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-27051 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6635 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-33686 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6734 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-40420 usd
us-gaap Net Income Loss
NetIncomeLoss
-32065 usd
us-gaap Net Income Loss
NetIncomeLoss
-25605 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-200 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
9000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21065 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14805 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25200 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2590 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
10377 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2590 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35577 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-18475 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
20772 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18475 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20772 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66140 usd
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34075 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zfWMV97kt4B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zvw8demNjv6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zYck0xxLWNki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial Statement Reclassification</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5920000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5920000 shares
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800 usd
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
12000 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
12000 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4200 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2400 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7800 usd
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9600 usd

Files In Submission

Name View Source Status
0001683168-22-005330-index-headers.html Edgar Link pending
0001683168-22-005330-index.html Edgar Link pending
0001683168-22-005330.txt Edgar Link pending
0001683168-22-005330-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mcle-20220630.xsd Edgar Link pending
mcle-20220630_cal.xml Edgar Link unprocessable
mcle-20220630_def.xml Edgar Link unprocessable
mcle-20220630_lab.xml Edgar Link unprocessable
mcle-20220630_pre.xml Edgar Link unprocessable
medicale_ex31.htm Edgar Link pending
medicale_ex32.htm Edgar Link pending
medicale_i10q-063022.htm Edgar Link pending
medicale_i10q-063022_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending